Preferred Pharmaceuticals Recalls Nature-Throid Tablets Due to CGMP Deviations
Preferred Pharmaceuticals is voluntarily recalling Nature-Throid tablets due to Current Good Manufacturing Practice (CGMP) deviations. The affected repackaged tablets were sold to three physicians in California and Georgia.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which typically involves a situation that might cause temporary or medically reversible health consequences. The source text does not report any specific illnesses or injuries, and the hazard is related to manufacturing deviations rather than a high-risk pathogen or structural defect.
Plain-English summary
Preferred Pharmaceuticals, Inc. is voluntarily recalling Nature-Throid, 1/2 Grain, 32.5 mg tablets. The recall was initiated on September 2, 2020, and was classified as Class II by the FDA. The reason for the recall is Current Good Manufacturing Practice (CGMP) deviations.
The affected product consists of 100-count tablets containing Thyroid U.S.P., Liothyronine (T3), and Levothyroxine (T4). The specific lots involved are L2717G (Exp. 12/31/2020), B2618A (Exp. 12/21/2020), and C1419P (Exp. 2/28/2021). The NDC number for the product is 68788-9283-01.
The repackaged tablets were sold to three physicians located in California and Georgia. The recall status is currently terminated as of April 25, 2024. Consumers and healthcare providers should check their inventory for these specific lot numbers and expiration dates.
The recalled product
- Product
- Nature-Throid, 1/2 Grain, 32.5 mg (Thyroid U.S.P. 1/2 gr. (32.5 mg)/Liothyronine (T3) 4.5mcg/Levothyroxine (T4) 19mch, 100-count tablets, Rx Only, Mfg: RLC Labs; Cave Creek, AZ, Preferred Pharmaceuticals, Inc. NDC 68788-9283-01
- Manufacturer
- Preferred Pharmaceuticals, Inc.
- Category
- Drug — Thyroid Medication
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Lot #: L2717G
- Exp. Date: 12/31/2020
- Lot #: B2618A
- Exp. Date: 12/21/2020
- Lot #: C1419P
- Exp. Date: 2/28/2021
Distribution
Part of a larger recall action
This product is one of 4 recalled by Preferred Pharmaceuticals, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 4 products in this recall →Related recalls
Same manufacturer · Preferred Pharmaceuticals, Inc.
See all →- ModeratePreferred Pharmaceuticals Recalls Lidocaine Ointment Due to Content Uniformity Failures
FDA (Drugs) · 2026-10-14
- HighGeri-Care artificial tears lubricant eye drops recalled over sterility assurance
FDA (Drugs) · 2026-04-15
- ModerateOndansetron blister packs recalled because tablets are falling out
FDA (Drugs) · 2025-12-24
- ModerateClindamycin Hydrochloride Capsules Recalled for cGMP Deviations
FDA (Drugs) · 2025-05-07
- HighIbuprofen Tablets Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2024-09-04
Same hazard · cgmp deviations
See all →- SevereBaxter Recalls Famotidine Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateBaxter Recalls Pantoprazole Sodium Infusion Bags Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Nexterone Amiodarone Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Vasopressin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Dexmedetomidine Hydrochloride Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
Similar recalls
- HighRLC Labs Recalls Nature-Throid Tablets Due to CGMP Deviations
FDA (Drugs) · 2020-09-23
- SeverePD-Rx Recalls Nature-Throid Tablets Due to CGMP Deviations and Sub-Potency Risk
FDA (Drugs) · 2020-10-14
- CriticalRLC Labs Recalls Subpotent Nature Throid Thyroid Medication
FDA (Drugs) · 2020-09-23
- SevereRLC Labs Recalls WP Thyroid Tablets Due to CGMP Deviations
FDA (Drugs) · 2020-09-23
- ModerateLloyd Inc. Recalls Levothroid Tablets Due to cGMP Deviations
FDA (Drugs) · 2012-12-12
- ModeratePrescription Tadalafil tablets recalled for manufacturing process deviations
FDA (Drugs) · 2023-04-12